| Not Yet Recruiting | Cytokine Armored GPC3 Specific Chimeric Antigen Receptor Expressing T-cells in Adults With Solid Tumors NCT07224568 | Seattle Children's Hospital | Phase 1 |
| Recruiting | Hypofractionated, 3-week, Preoperative Proton or X-ray Radiotherapy for Patients With Localized Soft Tissue Sa NCT07169344 | Oslo University Hospital | Phase 2 |
| Recruiting | Dose-escalated, Hypofractionated, Definitive Proton Radiotherapy for Patients With Inoperable Soft Tissue Sarc NCT07173972 | Oslo University Hospital | Phase 2 |
| Recruiting | Immunotherapy for Solid Tumor Malignancies in Pediatrics Using Interleukin-15 and -21 Armored Glypican-3-speci NCT07148050 | Seattle Children's Hospital | Phase 1 |
| Recruiting | Immunotherapy For Adults With GPC3-Positive Solid Tumors Using IL-15 and IL-21 Armored GPC3-CAR T Cells NCT06198296 | Baylor College of Medicine | Phase 1 |
| Recruiting | A Study of Mirdametinib in Combination With Palbociclib in People With Liposarcoma NCT06843967 | Memorial Sloan Kettering Cancer Center | Phase 1 / Phase 2 |
| Recruiting | Silmitasertib (CX-4945) in Combination With Chemotherapy for Relapsed Refractory Solid Tumors NCT06541262 | Milton S. Hershey Medical Center | Phase 1 / Phase 2 |
| Not Yet Recruiting | Investigating Engagement Patterns and Participation Trends Among Liposarcoma Patients NCT06039046 | Power Life Sciences Inc. | — |
| Recruiting | BTX-A51 in Patients With Liposarcoma or CIC-rearranged Sarcoma NCT06414434 | Michael Wagner, MD | Phase 1 |
| Recruiting | Interleukin-15 and -21 Armored Glypican-3-specific Chimeric Antigen Receptor Expressed in T Cells for Pediatri NCT04715191 | Baylor College of Medicine | Phase 1 |
| Terminated | NM32-2668 in Adult Patients With Selected Advanced Solid Tumors NCT06299163 | Numab Therapeutics AG | Phase 1 |
| Recruiting | NRSTS2021, A Risk Adapted Study Evaluating Maintenance Pazopanib, Limited Margin, Dose-Escalated Radiation The NCT06239272 | St. Jude Children's Research Hospital | Phase 1 / Phase 2 |
| Recruiting | MASCT-I Combined With Doxorubicin and Ifosfamide for First-line Treatment of Advanced Soft Tissue Sarcoma NCT06277154 | HRYZ Biotech Co. | Phase 2 |
| Withdrawn | Study of PF-07224826, as a Single Agent or in Combination With Endocrine Therapy in Participants With Breast C NCT05905341 | Pfizer | Phase 1 |
| Withdrawn | Phase 2 Study of 9-ING-41 With Chemotherapy in Sarcoma NCT05116800 | Brown University | Phase 2 |
| Terminated | ATX-101 in Advanced Dedifferentiated Liposarcoma and Leiomyosarcoma NCT05116683 | Benjamin Izar | Phase 2 |
| Recruiting | Precision Medicine Approaches for Neoadjuvant Therapy in High-risk Sarcoma Patients NCT07432932 | Royal Marsden NHS Foundation Trust | — |
| Unknown | A Study of OR2805, a Monoclonal Antibody Targeting CD163, Alone and in Combination With Anticancer Agents NCT05094804 | OncoResponse, Inc. | Phase 1 / Phase 2 |
| Withdrawn | A Phase 2 Study of 9-ING-41Combined With Chemotherapy in Adolescents and Adults With Advanced Sarcomas NCT04906876 | Brown University | Phase 2 |
| Active Not Recruiting | Interleukin-15 Armored Glypican 3-specific Chimeric Antigen Receptor Expressed in T Cells for Pediatric Solid NCT04377932 | Baylor College of Medicine | Phase 1 |
| Active Not Recruiting | Interleukin-15 Armored Glypican 3-specific Chimeric Antigen Receptor Expressed in Autologous T Cells for Solid NCT05103631 | Baylor College of Medicine | Phase 1 |
| Recruiting | APG-115 in Combination With PD-1 Inhibitor in Patients With Advanced Liposarcoma or Advanced Solid Tumors NCT04785196 | Ascentage Pharma Group Inc. | Phase 1 / Phase 2 |
| Completed | The Registry of Oncology Outcomes Associated With Testing and Treatment NCT04028479 | Taproot Health | — |
| Recruiting | Surgery With or Without Neoadjuvant Chemotherapy in High Risk RetroPeritoneal Sarcoma NCT04031677 | European Organisation for Research and Treatment of Cancer - EORTC | Phase 3 |
| Withdrawn | Selinexor in Combination With Ixazomib for the Treatment of Advanced Sarcoma NCT03880123 | Matthew Ingham | Phase 1 |
| Active Not Recruiting | Study to Test the Safety and Tolerability of PF-07220060 in Participants With Advance Solid Tumors NCT04557449 | Pfizer | Phase 2 |
| Recruiting | Identification of a New Blood Biomarker for the Diagnosis and Prognosis of Liposarcomas NCT04224064 | Institut du Cancer de Montpellier - Val d'Aurelle | N/A |
| Active Not Recruiting | Talimogene Laherparepvec and Radiation Therapy in Treating Patients With Newly Diagnosed Soft Tissue Sarcoma T NCT02923778 | National Cancer Institute (NCI) | Phase 2 |
| Completed | A Phase II Study of Eribulin and Pembrolizumab in Soft Tissue Sarcomas NCT03899805 | Dana-Farber Cancer Institute | Phase 2 |
| Withdrawn | Study on Leiomyosarcoma, Liposarcomas and Synovial Sarcoma With Trabectedin NCT03773510 | Italian Sarcoma Group | Phase 3 |
| Completed | Lenvatinib and Eribulin in Advanced Soft Tissue Sarcoma NCT03526679 | National Taiwan University Hospital | Phase 1 / Phase 2 |
| Active Not Recruiting | Eribulin and Radiation Therapy in Treating Patients With Retroperitoneal Liposarcoma That Can Be Removed by Su NCT03361436 | OHSU Knight Cancer Institute | Phase 1 |
| Completed | The FGF/FGFR Signalling Pathway: NCT03303885 | Centre Hospitalier Universitaire de Nice | — |
| Unknown | Hypofractionated Radiotherapy With Sequential Chemotherapy in Marginally Resectable Soft Tissue Sarcomas of Ex NCT03651375 | Maria Sklodowska-Curie National Research Institute of Oncology | Phase 2 |
| Terminated | Patient Reported Outcome Measures (PROMs) With Trabectedin NCT03959033 | University of Leeds | — |
| Completed | Sitravatinib in Advanced Liposarcoma and Other Soft Tissue Sarcomas NCT02978859 | Columbia University | Phase 2 |
| Unknown | A Phase II Study Assessing Efficacy & Safety of Ribociclib in Patients With Advanced Well/Dedifferentiated Lip NCT02571829 | Hadassah Medical Organization | Phase 2 |
| Completed | Doxorubicin With Upfront Dexrazoxane for the Treatment of Advanced or Metastatic Soft Tissue Sarcoma NCT02584309 | Washington University School of Medicine | Phase 2 |
| Unknown | Detection of Circulating Tumor Cells in Patients With Sarcomas NCT02983539 | AC Camargo Cancer Center | — |
| Terminated | Study to Compare the Safety and Efficacy of CMB305 With Atezolizumab to Atezolizumab Alone in Participants Wit NCT02609984 | Immune Design, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | Phase 2 |
| Completed | Study of Safety and Efficacy of HDM201 in Combination With LEE011 in Patients With Liposarcoma NCT02343172 | Novartis Pharmaceuticals | Phase 1 |
| Completed | Efatutazone Dihydrochloride in Treating Patients With Previously Treated Myxoid Liposarcoma That Cannot Be Rem NCT02249949 | Alliance for Clinical Trials in Oncology | Phase 2 |
| Recruiting | Trabectedin Plus Radiotherapy in Soft Tissue Sarcoma Patients NCT02275286 | Grupo Espanol de Investigacion en Sarcomas | Phase 1 / Phase 2 |
| Active Not Recruiting | Radiation Therapy With or Without Combination Chemotherapy or Pazopanib Before Surgery in Treating Patients Wi NCT02180867 | National Cancer Institute (NCI) | Phase 2 / Phase 3 |
| Completed | SARC024: A Blanket Protocol to Study Oral Regorafenib in Patients With Selected Sarcoma Subtypes NCT02048371 | Sarcoma Alliance for Research through Collaboration | Phase 2 |
| Completed | Efficacy Study on Trabectedin in Retroperitoneal Leiomyosarcoma and Well Differentiated/Dedifferentiated Lipos NCT02247544 | Italian Sarcoma Group | Phase 2 |
| Completed | Study of Pazopanib in the Treatment of Surgically Unresectable or Metastatic Liposarcoma NCT01506596 | Vector Oncology | Phase 2 |
| Completed | Combination Therapy of Gemcitabine and Trabectedin in L-sarcomas NCT01426633 | Heidelberg University | Phase 1 |
| Completed | PD0332991 (Palbociclib) in Patients With Advanced or Metastatic Liposarcoma NCT01209598 | Memorial Sloan Kettering Cancer Center | Phase 2 |
| Completed | Assessment of Helical Tomotherapy Radiotherapy (54 Gy) Followed by Surgery in Retro-peritoneal Liposarcoma NCT01841047 | Institut Bergonié | N/A |
| Completed | Phase II Study of Sunitinib Malate for Metastatic and/or Surgically Unresectable Soft Tissue Sarcoma NCT00400569 | H. Lee Moffitt Cancer Center and Research Institute | Phase 2 |
| Completed | Bevacizumab and Radiation Therapy for Sarcomas NCT00356031 | Massachusetts General Hospital | Phase 2 |
| Completed | Study of AP23573/MK-8669 (Ridaforolimus), A Mammalian Target of Rapamycin (mTOR) Inhibitor, in Participants Wi NCT00093080 | Merck Sharp & Dohme LLC | Phase 2 |
| Completed | An Analysis of the Response of Human Tumor Microvascular Endothelium to Ionizing Radiation NCT00132704 | Memorial Sloan Kettering Cancer Center | — |
| Completed | A Study to Assess Treatment With 2 Different Dosing Schedules of Trabectidin Administered to Patients With Adv NCT00060944 | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | Phase 2 |